

CREATININE ASSAY

Dual Vial Liquid Stable

Enzymatic creatinine assays have less interference than older Jaffe creatinine assays. Studies from leading clinical journals have shown that interference with Jaffe creatinine assays may lead to inaccuracies in estimated glomerular filtration rates that are clinically important, especially in children and neonates.¹ Diazyme's Enzymatic Creatinine is intended for the in vitro quantitative determination of creatinine in serum and urine. The assay is cost effective and provides outstanding reagent stability combined with the added convenience of instrument specific packing for several major instrument families.

DIAZYME CREATININE ASSAY ADVANTAGES

- Diazyme's enzymatic methodology is a better clinical choice than the older Jaffe method for the accurate measurement of creatinine, especially for neonates, pediatrics, and hematology units.²
- Significantly reduced interference with no cuvette staining
- Wide range of instrument parameters available for facilitating and simplifying implementation
- Liquid stable reagent and controls requires no reagent preparation, saving time and reducing sample handling

REGULATORY STATUS

510(k) Cleared



AVAILABLE INSTRUMENT SPECIFIC PACKAGING

- Roche
- Beckman
- Hitachi
- AU Series



CREATININE ASSAY


Dual Vial Liquid Stable



ASSAY SPECIFICATIONS

Method	Enzymatic Assay
Sample Type & Volume	• Serum • Urine Sample Volume 8 µL
Method Correlation	Serum: N = 55 y-intercept = 0.0643 Slope = 0.9467 R ² = 0.9981 Urine: N = 51 y-intercept = -0.0518 Slope = 1.0002 R ² = 0.9968
Linear Range	Serum: 0.14 - 13.56 mg/dL (12 - 1200 µmol/L) Urine: 0.14 - 141.25 mg/dL (12 - 12500 µmol/L)
LOD	12 µmol/L (0.14 mg/dL)
Calibration Levels	1-Point Calibration
Traceability	Standard traceable NIST's SRM 914a
Reagent On-Board Stability	Opened: 4 weeks when stored at 2-8°C

Creatinine Assay Procedure*



*Analyzer Dependent

Parameter questions for Enzymatic Creatinine Assay should be addressed to Diazyme technical support. Please call 858.455.4768 or email support@diazyme.com

1. Cobbaert, C. M., H. Baadenhuijsen, and C. W. Weykamp. "Prime Time for Enzymatic Creatinine Methods in Pediatrics." *Clinical Chemistry* 55.3 (2009): 549-58. Web.
2. Badiou S, Dupuy AM, Descamps B, Cristolead, JP. Comparison between the enzymatic vitros assay for creatinine determination and three other methods adapted on the Olympus analyzer, *Journal of Clinical Laboratory Analysis* 2003;17, 235 - 240

ASSAY PRECISION

The assay was evaluated according to Clinical Laboratory Standards Institute EP5-A guidelines. Four serum specimens were tested on a Hitachi 917 twice daily, in duplicates over 20 days.

Serum Testing	Within-Run Precision (80 Data Points)			
	0.75 mg/dL (66.3 µM)	1.41 mg/dL (125 µM)	4.11 mg/dL (346 µM)	10.28 mg/dL (908.7 µM)
Mean mg/dL (µM)	0.74 (65.4)	1.38 (122.3)	4.04 (357.5)	10.28 (908.7)
SD mg/dL (µM)	0.015 (1.3)	0.015 (1.37)	0.029 (2.54)	0.015 (1.3)
CV%	2.1%	1.1%	0.7%	0.1%
Serum Testing	Total Precision (80 Data Points)			
	0.75 mg/dL (66.3 µM)	1.41 mg/dL (125 µM)	4.11 mg/dL (346 µM)	10.28 mg/dL (908.7 µM)
Mean mg/dL (µM)	0.74 (65.4)	1.38 (122.3)	4.04 (357.5)	10.28 (908.7)
SD mg/dL (µM)	0.022 (1.9)	0.026 (2.29)	0.058 (5.11)	0.014 (12.4)
CV%	3.0%	1.9%	1.4%	1.4%

The assay precision was evaluated with urine samples with a modified EP10 protocol. Within-run precision; 21 replicates of commercial urine controls were tested. Total precision; 2 runs of each commercial urine control were performed consecutively for 5 days.

Urine Testing	Within-Run Precision (21 Data Points)		
	Level 1	Level 2	Level 3
Mean mg/dL (µM)	29.09 (2572)	87.1 (7711)	196.7 (17407)
SD mg/dL (µM)	0.1 (8.84)	0.27 (23.60)	0.90 (79.71)
CV%	0.36%	0.31%	0.46%
Urine Testing	Total Precision (20 Data Points)		
	Level 1	Level 2	Level 3
Mean mg/dL (µM)	29.86 (2640)	87.7 (7765)	195 (17265)
SD mg/dL (µM)	0.79 (69.8)	0.67 (59.2)	1.19 (105.2)
CV%	2.64%	0.76%	0.60%

ASSAY INTERFERENCE

Interference for the Diazyme Creatinine Assay was evaluated on the Hitachi 917. The following substances normally present in serum produced less than 10% deviation at the listed concentrations:

Triglyceride:	up to 1000 mg/dL	Ascorbic Acid:	up to 10 mM
Bilirubin (Conjugate):	up to 30 mg/dL	Bilirubin:	up to 40 mg/dL
Hemoglobin:	up to 500 mg/dL		

The following substances normally present in urine produced less than 10% deviation at the listed concentrations:

Triglyceride:	up to 1000 mg/dL	Ascorbic Acid:	up to 10 mM
Bilirubin (Conjugate):	up to 40 mg/dL	Bilirubin:	up to 40 mg/dL
Hemoglobin:	up to 1000 mg/dL		

DIAZYME LABORATORIES

12889 Gregg Court, Poway, CA 92064

PO Box 85608, San Diego, CA 92186

Tel: 858-455-4768 888-DIAZYME

www.diazyme.com sales@diazyme.com

DIAZYME EUROPE GMBH

Zum Windkanal 21, 01109 Dresden, Deutschland

Tel. +49 (0) 351 886 3300 Fax +49 (0) 351 886 3366

sales@diazyme.de

SHANGHAI DIAZYME CO., LTD.

Room 201,1011 Halei Road, Zhangjiang Hi-tech Park

Shanghai, 201203, People's Republic of China

Tel: 086-21-51320668 Fax: 086-21-51320663

www.lanyuanbio.com service@lanyuanbio.com

